All Stories

  1. ExtracorporeaL life support and Modification Of Hemostasis: the ELMOH trial: hemostatic changes during the first 48 h of VV- and VA-ECMO: a prospective multicenter cohort study
  2. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection
  3. Statistical analysis plan for the biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2) study: An international randomised controlled multicentre trial
  4. Effect of a single small volume fluid bolus with balanced or un-balanced fluids on chloride and acid–base status: a prospective randomized pilot study (the FLURES-trial)
  5. Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
  6. Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis
  7. Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
  8. Immunological sub-phenotypes and response to Convalescent Plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial.
  9. CCL14 Predicts Oliguria and Dialysis Requirement in Patients with Moderate to Severe Acute Kidney Injury
  10. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
  11. Lack of association between HLA and asymptomatic SARS-CoV-2 infection
  12. A global perspective on acute kidney injury after major surgery: much needed insights and sobering results
  13. Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
  14. Initiation of continuous renal replacement therapy versus intermittent hemodialysis in critically ill patients with severe acute kidney injury: a secondary analysis of STARRT-AKI trial
  15. Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU
  16. Performance of urinary C–C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis
  17. Ferroptosis and pyroptosis signatures in critical COVID-19 patients
  18. The effects of differing anticoagulant regimes on blood quality after cell salvage in coronary artery bypass grafting (CABG): a pilot study
  19. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
  20. Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review
  21. Potential of Urine Biomarkers CHI3L1, NGAL, TIMP-2, IGFBP7, and Combinations as Complementary Diagnostic Tools for Acute Kidney Injury after Pediatric Cardiac Surgery: A Prospective Cohort Study
  22. Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury
  23. Correction: Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial
  24. Fluid balance and renal replacement therapy initiation strategy: a secondary analysis of the STARRT-AKI trial
  25. Acute and chronic cardiovascular consequences of acute kidney injury: a systematic review and meta-analysis.
  26. Adult essential extracorporeal membrane oxygenation (ECMO) skills for use in an e-learning program for ICU physicians, nurses and perfusionists: a consensus by a modified Delphi questionnaire
  27. Characterising acute kidney injury: The complementary roles of biomarkers of renal stress and renal function
  28. Impact of mean perfusion pressure and vasoactive drugs on occurrence and reversal of cardiac surgery-associate acute kidney injury: A cohort study
  29. Predictive value of the renal resistive index in the immediate postoperative period after kidney transplantation on short- and long-term graft and patient outcomes
  30. Impact of tight blood glucose control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients: the TGC-fast randomized controlled trial
  31. Impact of tight blood glucose control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients: the TGC-fast randomized controlled trial
  32. Acute kidney injury in critical COVID-19: a multicenter cohort analysis in seven large hospitals in Belgium
  33. Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’
  34. Targeting ferroptosis protects against experimental (multi)organ dysfunction and death
  35. Prediction of cardiac surgery associated - acute kidney injury (CSA-AKI) by healthcare professionals and urine cell cycle arrest AKI biomarkers [TIMP-2]*[IGFBP7]: A single center prospective study (the PREDICTAKI trial)
  36. Illness cognitions and health-related quality of life in liver transplant patients related to length of stay, comorbidities and complications
  37. The AKI care bundle: all bundle components are created equal—are they?
  38. Augmented renal clearance in critically ill COVID-19 patients: Forewarned is forearmed
  39. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
  40. The Prognostic Value of Cardiac Biomarkers and Echocardiography in Critical COVID-19
  41. Impact of AKI care bundles on kidney and patient outcomes in hospitalized patients: a systematic review and meta-analysis
  42. Patients with Severe Lactic Acidosis in the Intensive Care Unit: A Retrospective Study of Contributing Factors and Impact of Renal Replacement Therapy
  43. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
  44. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
  45. Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
  46. Integration of Equipoise into Eligibility Criteria in the STARRT-AKI Trial
  47. Acute kidney injury in the critically ill: an updated review on pathophysiology and management
  48. The importance of the urinary output criterion for the detection and prognostic meaning of AKI
  49. When should we start renal-replacement therapy in critically ill patients with acute kidney injury: do we finally have the answer?
  50. Prevention of Cardiac Surgery–Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial
  51. Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial
  52. Targeting ferroptosis protects against multiorgan dysfunction and death.
  53. Temporal changes in the epidemiology, management, and outcome from acute respiratory distress syndrome in European intensive care units: a comparison of two large cohorts
  54. What every Intensivist should know about COVID-19 associated acute kidney injury
  55. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol
  56. Publisher Correction: COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  57. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  58. Acute cardiorenal syndrome in acute heart failure: focus on renal replacement therapy
  59. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
  60. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
  61. Comparison of predication of Acute Kidney Injury after cardiac surgery by health care providers versus the biomarker [TIMP-2]*[IGFBP7] and scoring systems. Protocol for a prospective single center observational study (PREDICTAKI)
  62. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury
  63. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans
  64. Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort
  65. A Multinational Observational Study Exploring Adherence With the Kidney Disease
  66. Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibili...
  67. Focus on metabolism, acute kidney injury and its influence on systemic organs
  68. Protocol and statistical analysis plan for the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury—REVERSE‐AKI randomized controlled pilot trial
  69. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study
  70. Net Ultrafiltration Prescription and Practice Among Critically Ill Patients Receiving Renal Replacement Therapy
  71. Lung–kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup
  72. Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section
  73. Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion
  74. Evaluation of the quality of the communication and emotional support during the donation procedure: The use of the donor family questionnaire (DFQ)
  75. Contrast-associated acute kidney injury: does it really exist, and if so, what to do about it?
  76. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy
  77. Cytokine removal in human septic shock: Where are we and where are we going?
  78. Adherence to guidelines for the management of donors after brain death
  79. Model for end-stage liver disease score and hemodynamic instability as a predictor of poor outcome in early transjugular intrahepatic portosystemic shunt treatment for acute variceal hemorrhage
  80. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury
  81. Plasma neutrophil gelatinase-associated lipocalin (NGAL) for timing of initiation of renal replacement therapy for acute kidney injury?
  82. Paving the way for precision medicine v2.0 in intensive care by profiling necroinflammation in biofluids
  83. Global epidemiology and outcomes of acute kidney injury
  84. Update on Perioperative Acute Kidney Injury
  85. Development of key interventions and quality indicators for the management of an adult potential donor after brain death: a RAND modified Delphi approach
  86. Angiotensin inhibition in patients with acute kidney injury: Dr. Jekyll or Mr. Hyde?
  87. Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults
  88. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP)
  89. Low flow extracorporeal CO2 removal in ARDS patients: a prospective short-term crossover pilot study
  90. Brief Orals
  91. Epidemiology of cardiac surgery-associated acute kidney injury
  92. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017
  93. A nephrologist should be consulted in all cases of acute kidney injury in the ICU: No
  94. Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference
  95. Diagnostic work-up and specific causes of acute kidney injury
  96. Recovery after Acute Kidney Injury
  97. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury
  98. Diagnosis of cardiac surgery-associated acute kidney injury: differential roles of creatinine, chitinase 3-like protein 1 and neutrophil gelatinase-associated lipocalin: a prospective cohort study
  99. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup
  100. The intensive care medicine agenda on acute kidney injury
  101. Assessment of the Optimal Operating Parameters during Extracorporeal CO2 Removal with the Abylcap® System
  102. Diagnosis of cardiac surgery-associated acute kidney injury from functional to damage biomarkers
  103. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications
  104. Nomenclature for renal replacement therapy in acute kidney injury: basic principles
  105. Defining the characteristics and expectations of fluid bolus therapy: A worldwide perspective
  106. Understanding oliguria in the critically ill
  107. Long-term outcome in ICU patients with acute kidney injury treated with renal replacement therapy: a prospective cohort study
  108. Recommendations for further improvement of the deceased organ donation process in Belgium
  109. Care pathways for organ donation after brain death: guidance from available literature?
  110. Zero deaths from AKI by 2025: focus on awareness and therapy
  111. The perceived quality of interprofessional teamwork in an intensive care unit: A single centre intervention study
  112. Applications for Detection of Acute Kidney Injury Using Electronic Medical Records and Clinical Information Systems: Workgroup Statements from the 15th ADQI Consensus Conference
  113. Impact of Electronic-Alerting of Acute Kidney Injury: Workgroup Statements from the 15th ADQI Consensus Conference
  114. Urinary chitinase 3-like protein 1 for early diagnosis of acute kidney injury: a prospective cohort study in adult critically ill patients
  115. How to Solve the Underestimated Problem of Overestimated Sodium Results in the Hypoproteinemic Patient
  116. Treating Acute Kidney Injury. One Less Weapon in the Armamentarium?
  117. Precision Fluid Management in Continuous Renal Replacement Therapy
  118. Acute Kidney Injury in Cardiorenal Syndrome Type 1 Patients: A Systematic Review and Meta-Analysis
  119. Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery
  120. Faculty of 1000 evaluation for The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock.
  121. Early diagnosis of AKI in the ICU: urinary chitinase 3-like protein 1 as a novel renal troponin
  122. Relative Low Flow Extra Corporeal Co2-Removal in Ards Patients: A Pilot Study
  123. Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study
  124. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study
  125. Fluid challenges in intensive care: the FENICE study
  126. Influence of severity of illness on neutrophil gelatinase-associated lipocalin performance as a marker of acute kidney injury: a prospective cohort study of patients with sepsis
  127. Comparison of different equations to assess glomerular filtration in critically ill patients
  128. Variation in Risk and Mortality of Acute Kidney Injury in Critically Ill Patients: A Multicenter Study
  129. Tissue Inhibitor Metalloproteinase-2 (TIMP-2)*IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI
  130. Contrast-associated AKI in the critically ill
  131. Acute kidney injury survivors should have long-term follow-up
  132. Belgian Modified Classification of Maastricht for Donors After Circulatory Death
  133. Four phases of intravenous fluid therapy: a conceptual model †
  134. The 12th consensus conference of the Acute Dialysis Quality Initiative (ADQI XII) †
  135. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers
  136. AKI in early sepsis is a continuum from transient AKI without tubular damage over transient AKI with minor tubular damage to intrinsic AKI with severe tubular damage
  137. A Multiscale Entropy-Based Tool for Scoring Severity of Systemic Inflammation*
  138. Severe lactic acidosis in critically ill patients with acute kidney injury treated with renal replacement therapy
  139. How has urinary proteomics contributed to the discovery of early biomarkers of acute kidney injury?
  140. CLINICAL ACUTE KIDNEY INJURY 1
  141. “Piece” of mind: End of life in the intensive care unit Statement of the Belgian Society of Intensive Care Medicine
  142. What’s new in the controversy on the renal/tissue toxicity of starch solutions?
  143. Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)
  144. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
  145. Implementing the Kidney Disease
  146. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy
  147. A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*
  148. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion
  149. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
  150. Cardiorenal Syndrome Type 3: Pathophysiologic and Epidemiologic Considerations
  151. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
  152. Pathophysiology of the Cardiorenal Syndromes: Executive Summary from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI)
  153. Urinary output and fractional excretion of sodium and urea as indicators of transient versus intrinsic acute kidney injury during early sepsis
  154. Urinary chitinase 3-like 1, a novel biomarker for acute kidney injury in adult cardiac intensive care patients: a pilot study
  155. ESICM 2012 MONDAY SESSIONS 15 October, 2012
  156. Mortality after surgery in Europe: a 7 day cohort study
  157. Renal Physiology in the Critically Ill Obese Patient
  158. Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure
  159. Impact of real-time electronic alerting of acute kidney injury on therapeutic intervention and progression of RIFLE class*
  160. Recommendations for the Management of Crush Victims in Mass Disasters
  161. Section I: Definitions and Basic Concepts
  162. Epidemiology of contrast-associated acute kidney injury in ICU patients: reply to Valette and du Cheyron
  163. Prerenal Azotemia
  164. AKI patients have worse long-term outcomes, especially in the immediate post-ICU period
  165. Contrast Nephropathy
  166. Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis
  167. In Reply to ‘Intra-abdominal Pressure Can Be Estimated Inexpensively by the Sagittal Abdominal Diameter'
  168. Serum urea concentration is probably not related to outcome in ICU patients with AKI and renal replacement therapy
  169. Clinical review: Use of renal replacement therapies in special groups of ICU patients
  170. Intra-abdominal Hypertension and Abdominal Compartment Syndrome
  171. Clinical Consequences of Acute Kidney Injury
  172. Morbidity and Mortality of Bloodstream Infections in Patients With Severe Burn Injury
  173. Defining acute kidney injury: playing hide-and-seek with the unknown man?
  174. Application of the RIFLE criteria in patients with crush-related acute kidney injury after mass disasters
  175. Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis
  176. AKI severity class doesn't tell all: the case for transient AKI
  177. Antimicrobial prophylaxis in liver transplant patients – a multicenter survey endorsed by the European Liver and Intestine Transplant Association
  178. A comparison of three methods to estimate baseline creatinine for RIFLE classification
  179. Pro/con debate: Continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?
  180. ARDS of Early or Late Onset
  181. Acute Kidney Injury in Critically Ill Patients with Cancer
  182. Abdominal decompression for intra-abdominal hypertension after simultaneous pancreas-kidney transplantation
  183. Epidemiology of Acute Kidney Injury
  184. Modern Classification of Acute Kidney Injury
  185. Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury
  186. Severe burn injury in europe: a systematic review of the incidence, etiology, morbidity, and mortality
  187. Thrombocytopenia and outcome in critically ill patients with bloodstream infection
  188. Intensive vs conventional blood glucose control in critically ill patients
  189. How to remove accumulated iodine in burn-injured patients
  190. Prerenal Acute Kidney Failure
  191. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis
  192. Epidemiology of infection in critically ill patients with acute renal failure
  193. Enterobacteriaceaebacteremia after liver transplantation
  194. Intensive insulin therapy: The swinging pendulum of evidence*
  195. The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury
  196. Development and validation of a model for prediction of mortality in patients with acute burn injury
  197. Acute kidney injury in the intensive care unit: It’s the gene, stupid!*
  198. The prevention of acute kidney injury: an in-depth narrative review Part 1: volume resuscitation and avoidance of drug- and nephrotoxin-induced AKI
  199. The value of procalcitonin to diagnose infection in critically ill patient: caveat emptor!
  200. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial
  201. Impact of local circumstances on outcome of renal casualties in major disasters
  202. Variation in critical care services across North America and Western Europe*
  203. Blood Stream Infections of Abdominal Origin in the Intensive Care Unit: Characteristics and Determinants of Death
  204. Epidemiology of acute kidney injury: How big is the problem?
  205. Timing of Initiation and Discontinuation of Renal Replacement Therapy in AKI: Unanswered Key Questions
  206. Trends in mortality in coronary artery bypass graft patients with acute renal failure
  207. Transvesical intra-abdominal pressure measurement using minimal instillation volumes: how low can we go?
  208. Development of a Clinical Research Agenda for Acute Kidney Injury Using an International, Interdisciplinary, Three-Step Modified Delphi Process
  209. Acute kidney injury in burns: a story of volume and inflammation
  210. Acute kidney injury: Epidemiology and assessment
  211. Service-oriented Subscription Management of Medical Decision Data in the Intensive Care Unit
  212. The Diagnosis of Relative Adrenal Insufficiency: The Long and Winding Road…
  213. Dynamics of C-reactive protein and white blood cell count in critically ill patients with nosocomial Gram positive vs. Gram negative bacteremia: a historical cohort study
  214. Health Implications of Antimicrobial Resistance for Patients With Acute Kidney Injury and Bloodstream Infection
  215. The effect of neuromuscular blockers in patients with intra-abdominal hypertension
  216. Relative adrenal insufficiency in patients with severe acute pancreatitis
  217. Semicontinuous intra-abdominal pressure measurement using an intragastric Compliance catheter
  218. Extrapancreatic Inflammation on Abdominal Computed Tomography as an Early Predictor of Disease Severity in Acute Pancreatitis
  219. The future of surgical critical care: A European perspective
  220. Earthquakes and crush syndrome casualties: Lessons learned from the Kashmir disaster
  221. A novel approach for prediction of tacrolimus blood concentration in liver transplantation patients in the intensive care unit through support vector regression
  222. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
  223. Incidence, Classification, and Outcomes of Acute Kidney Injury
  224. ACUTE KIDNEY INJURY 2007
  225. ACUTE KIDNEY INJURY, LENGTH OF STAY, AND COSTS IN PATIENTS HOSPITALIZED IN THE INTENSIVE CARE UNIT
  226. EPIDEMIOLOGY OF AKI IN THE ICU
  227. IMPLEMENTATION OF A REAL-TIME ELECTRONIC ALERT BASED ON THE RIFLE CRITERIA FOR ACUTE KIDNEY INJURY IN ICU PATIENTS
  228. LONG-TERM OUTCOME AFTER ACUTE KIDNEY INJURY IN CRITICALLY-ILL PATIENTS
  229. SEVERE INFECTION, SEPSIS AND ACUTE KIDNEY INJURY
  230. Acute kidney injury: epidemiology and diagnostic criteria
  231. RIFLE criteria provide robust assessment of kidney dysfunction and correlate with hospital mortality*
  232. Effect of fluconazole consumption on long-term trends in candidal ecology
  233. Current pharmacotherapeutic recommendations for acute pancreatitis
  234. Saline volume in transvesical intra-abdominal pressure measurement: enough is enough
  235. Clinical and Economic Outcomes in Critically Ill Patients with Nosocomial Catheter-Related Bloodstream Infections
  236. Outcome and changes over time in survival following severe burns from 1985 to 2004
  237. Would Patients with More Subtle Signs of Coagulopathy Have Benefited from Treatment with Activated Protein C?
  238. Colonization Status and Appropriate Antibiotic Therapy for Nosocomial Bacteremia Caused by Antibiotic-Resistant Gram-Negative Bacteria in an Intensive Care Unit
  239. Influence of Matching for Exposure Time on Estimates of Attributable Mortality Caused by Nosocomial Bacteremia in Critically Ill Patients
  240. Physiologic Consequences of Acute Renal Failure on the Critically Ill
  241. Assessment of renal function in recently admitted critically ill patients with normal serum creatinine
  242. Fluid vs. air for semicontinuous intra-abdominal pressure measurements using a compliance catheter
  243. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies
  244. Phenytoin intoxication in critically ill patients
  245. Acute Effects of Upright Position on Gas Exchange in Patients With Acute Respiratory Distress Syndrome
  246. Emergence of Antibiotic Resistance in Infected Pancreatic Necrosis
  247. Reflections on the definition, classification, and diagnostic evaluation of acute renal failure
  248. The assumed problem of air bubbles in the tubing during intra-abdominal pressure measurement
  249. Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study
  250. Effect of Nosocomial Bloodstream Infection on the Outcome of Critically Ill Patients with Acute Renal Failure Treated with Renal Replacement Therapy
  251. Absence of Excess Mortality in Critically Ill Patients With Nosocomial Escherichia coli Bacteremia
  252. Adrenal Insufficiency in Severe Acute Pancreatitis
  253. Estimates of attributable mortality of systemic candida infection in the ICU
  254. Acute Renal Failure in Patients with Sepsis in a Surgical ICU: Predictive Factors, Incidence, Comorbidity, and Outcome
  255. Is MRSA More Pathogenic in Critically Ill Patients?—Reply
  256. The Effect of Tube Thoracostomy on Oxygenation in ICU Patients
  257. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication*
  258. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa
  259. No early respiratory benefit with CVVHDF in patients with acute renal failure and acute lung injury
  260. Outcome and Attributable Mortality in Critically Ill Patients With Bacteremia Involving Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus
  261. Effects of nosocomial candidemia on outcomes of critically ill patients
  262. Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults?
  263. Clinical Characteristics of Septic Patients Developing Acute Renal Failure (ARF)
  264. Significant increase of activated partial thromboplastin time by heparinization of the radial artery catheter flush solution with a closed arterial catheter system
  265. Carsin H, et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns 2000;26:379–387
  266. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata
  267. Staphylococcal septicaemia in burns
  268. Ozumba UC, Jiburum BC. Bacteriology of burn wounds in Enugu, Nigeria. Burns 2000; 26(2): 178–80
  269. Modulation of liver graft hemodynamics by partial ablation of the splenic circuit: a way to increase hepatic artery flow?
  270. Inadequate Proof of Adverse Outcome Due to the Use of Fluconazole in Critically Ill Patients
  271. Antibiotic Resistance and Exposure to Different Generation Cephalosporins
  272. Tracheal Colonization in Pneumonia
  273. Biocompatibility and acute renal failure
  274. Use of continuous bispectral EEG monitoring to assess depth of sedation in ICU patients
  275. Management of Candidal Thrombophlebitis of the Central Veins: Case Report and Review
  276. The Organization of the European Renal Disaster Relief Task Force
  277. Different Types of Dialyzer Membranes: Does the Bio(in)compatibility Matter in the Treatment of ARF?
  278. Pathophysiology, Causes, and Prognosis of Acute Renal Failure in the Elderly
  279. Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol
  280. Definition, Classification, and Epidemiology of Acute Kidney Disease